A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Subjects With Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-11)
The primary objectives of this study are: Phase 1: To evaluate the safety of axicabtagene ciloleucel in combination with utomilumab and to identify the most appropriate dose and timing of utomilumab to carry forward into Phase 2 Phase 2: To evaluate the efficacy of axicabtagene ciloleucel and utomilumab in participants with refractory large B-cell lymphoma
View MoreAge
18 Years +
Sex
All
Healthy Volunteers
No
Medical Condition
Relapsed/Refractory Large B-cell Lymphoma
Gender
N/A
Date
November 2018 - May 2021
Study Type
Interventional
Study Phase
Phase 1
Product
Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel, Utomilumab
Palo Alto, California, United States, 94305
Santa Monica, California, United States, 90404
Tampa, Florida, United States, 33612
Boston, Massachusetts, United States, 02215
New York, New York, United States, 10032
Share Trial